PCA
EW icon

Pallas Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Pallas Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$632K Sell
7,891
-1,929
-20% -$159K 0.02% 438
2025
Q4 		$837K Sell
9,820
-128
-1% -$10.5K 0.03% 396
2025
Q3 		$774K Buy
9,948
+5,996
+152% +$468K 0.03% 402
2025
Q2 		$309K Buy
3,952
+884
+29% +$65.9K 0.01% 638
2025
Q1 		$222K Buy
+3,068
New +$220K 0.01% 663

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pallas Capital Advisors's EW Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Edwards Lifesciences (EW) stake by 20% in Q1 2026, selling an estimated $159K and leaving 7,891 shares worth $632K. The position accounts for 0.02% of the portfolio, ranked #438.

Pallas Capital Advisors first reported a position in EW in Q1 2025 and has held it in 5 quarters since. The position peaked at $837K in Q4 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Pallas Capital Advisors held 7,891 shares of Edwards Lifesciences worth $632K as of Q1 2026.
  • Pallas Capital Advisors sold 1,929 Edwards Lifesciences shares in Q1 2026, an estimated $159K.
  • Edwards Lifesciences made up 0.02% of Pallas Capital Advisors's portfolio in Q1 2026, its #438 holding.
  • Pallas Capital Advisors first reported a position in Edwards Lifesciences in Q1 2025 and has held it in 5 quarters since.
  • Pallas Capital Advisors's Edwards Lifesciences position peaked at $837K in Q4 2025.
  • 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.